

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

ABJ-136

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.5)

09/380835

INTERNATIONAL APPLICATION NO.
PCT/CH98/00091

INTERNATIONAL FILING DATE
March 6, 1998

PRIORITY DATE CLAIMED
March 11, 1997

TITLE OF INVENTION

Process for Preparing 1, 4-Disubstituted Piperidine Compounds

APPLICANT(S) FOR DO/EO/US

Max REY

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 18 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☒ Certificate of Mailing by Express Mail
19. ☒ Other items or information:

Form PCT/RO/101

Preliminary Amendment

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.5) 09/380835	INTERNATIONAL APPLICATION NO. PCT/CH98/00091	ATTORNEY'S DOCKET NUMBER ABJ-136
---	--	--

20. The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :					
<input checked="" type="checkbox"/>	Search Report has been prepared by the EPO or JPO		\$840.00		
<input type="checkbox"/>	International preliminary examination fee paid to USPTO (37 CFR 1.482)		\$670.00		
<input type="checkbox"/>	No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))		\$760.00		
<input type="checkbox"/>	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO		\$970.00		
<input type="checkbox"/>	International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)		\$96.00		
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$840.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	15 - 20 =	0	x \$18.00	\$0.00	
Independent claims	1 - 3 =	0	x \$78.00	\$0.00	
Multiple Dependent Claims (check if applicable).				<input type="checkbox"/>	\$0.00
TOTAL OF ABOVE CALCULATIONS =				\$840.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).				<input type="checkbox"/>	\$0.00
SUBTOTAL =				\$840.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$840.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).				<input checked="" type="checkbox"/>	\$40.00
TOTAL FEES ENCLOSED =				\$880.00	
				Amount to be: refunded	\$
				charged	\$

- ☒ A check in the amount of **\$880.00** to cover the above fees is enclosed.
- ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **12-2147** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Anthony M. Lorusso
LORUSSO & LOUD
440 Commercial Street
Boston, MA 02109
(617) 227-0700


SIGNATURE

Anthony M. Lorusso

NAME

25,059

REGISTRATION NUMBER

9/9/99

DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:)	Express Mail Label No.:
May REY)	EM424409325US
Serial No.: Corres. to W098/40376)	Date of Deposit: 09/09/99
Filed: September 9, 1999)	Atty. Docket No.: ABJ-136
For: Process for Preparing)	
1, 4-Disubstituted Piperidine)	
Compounds)	

Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to examination of the captioned application and prior to calculation of the fees, please preliminarily amend the application as follows:

IN THE CLAIMS

Please amend the claims as follows:

4. (Amended) The process in accordance with [one of the Patent Claims 1 or 2] claim 1, wherein the compound of formula (1) has two substituents R, which are different from hydrogen, one substituent R being on the pyridine ring and one substituent R on the benzoring.

6. (Amended) The process in accordance with [one of the Patent Claims 1 to 3] claim 1, wherein the compound of formula (1) only has a single substituent R, which is different from hydrogen,

this substituent R being fixed in R-position.

7. (Amended) The process in accordance with [one of the Patent Claims 1 to 6] claim 1, wherein

Y means $-\text{CH}_2 - \text{CH}_2$;

R^1 means $(\text{C}_1 - \text{C}_5)$ -alkyl, preferably ethyl;

R^2 means $(\text{C}_1 - \text{C}_5)$ -alkyl, benzyl, vinyl, or dimethyl amino, preferably methyl;

Z means $-\text{C}(\text{O})\text{R}^1$; $-\text{C}(\text{O})\text{OR}^1$, preferably $-\text{C}(\text{O})\text{OR}^1$, and preferably $-\text{C}(\text{O})-\text{C}_2\text{H}_5$.

8. (Amended) The process in accordance with [one of the Patent Claims 1 to 7] claim 1, wherein a halogen compound is used as the metal compound.

11. (Amended) The process in accordance with [one of the Patent Claims 1 to 9] claim 1, wherein zinc, lithium, sodium, potassium, magnesium, or calcium or alloys containing zinc, lithium, sodium, potassium, magnesium, and/or calcium, calcium hydride, sodium borhydride, or lithium aluminum hydride is used as reducing agent.

12. (Amended) The process in accordance with [one of the patent Claims 1 to 9] claim 1, wherein an alloy of an alkali metal, a metal of the IIInd main group, or the IIInd subgroup of the periodic table with zinc, a zinc-copper alloy, or a potassium-

graphite inclusion compound is the reducing agent.

13. (Amended) The process in accordance with [one of the patent Claims 1 to 12] claim 1, wherein 1,4-dioxane, 1,2-dimethoxyethane, tetrahydrofuran, diethylene glycol dimethyl ether, tert.-butyl-methyl ether, pyridine, or triethyl amine is used as solvent.

14. (Amended) The process in accordance with [one of the Patent Claims 1 to 13] claim 1, wherein the compound 4-(8-fluoro-5,6-dihydro-11H-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-ylidene)-1-piperidine carboxylic acid ethyl ester is produced.


15. (Amended) The compound[s] produced in accordance with [one of the Patent Claims 1 to 14] claim 1.

REMARKS

Claims 1 to 15 have been rewritten to eliminate multiple dependencies.

Please charge any fee deficiency, or credit any overpayment, to Deposit Account No. 12-2147. If there is a problem with this submission, or the Examiner requires any further information, it is requested that the undersigned be contacted by collect telephone call.

Respectfully submitted,
LORUSSO & LOUD




Anthony M. Lorusso
Reg. No. 25,059

Dated: September 9, 1999
LORUSSO & LOUD
440 Commercial Street
Boston, MA 02109
Tel: (617) 227-0700
Fax: (617) 723-4609

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this document along with any paper or document referred to as being attached or enclosed is being deposited with the United States Postal Service on this 9th day of September, 1999 in an envelope as "Express Mail Post Office to Addressee" Mailing Label No. EM424409325US addressed to: Box PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.



Jacob F. Filene

Process for preparing 1, 4-disubstituted piperidine compounds

The present invention concerns a new process for producing 1,4-disubstituted piperidine compounds, in particular 4-(5-6-dihydro-11*H*-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-ylidene)-1-piperidine compounds. The compound 4-(8-chloro-5,6-dihydro-11*H*-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-ylidene)-1-piperidine carboxylic acid ethyl ester (loratidine) has acquired particular significance as an H₁ antihistamine. Different processes for producing these compounds are described in the literature. However, the known processes have diverse disadvantages.

US 4,731,447 describes a multiple-stage process, which, among other things, includes a Grignard reaction, in which it is necessary to work with an intermediary protective group on the piperidine nitrogen. The total yield is reduced because of the number of process steps which are, in part, difficult to perform. The use of *n*-butyl lithium described there requires extreme caution, as well as cyclization in super-acid conditions at very low temperatures. The process requires expensive reagents and also creates environmental problems. The other known processes also have similar disadvantages.

The process in accordance with the present invention on the whole has only a few process steps and requires no intermediate protective group on the piperidine nitrogen, a comparatively high yield being achieved. The process in accordance with the invention has no critical process steps for production. Also no reagents or solvents to be characterized as toxic, but at most slightly toxic or irritating, are used, so that all reactions could be carried out at ordinary reaction temperatures and in ordinary facilities. All products obtained in the process occur in crystalline form. No environmentally hazardous substances are used, created, or formed as intermediate products. The metals used, titanium and zinc, precipitate out of the reaction as non-toxic and easily reusable or disposable titanium oxides and zinc(II)tetramine complexes.

The present invention is defined in the Patent Claims. In particular, the present invention concerns a process for creating 1,4-disubstituted piperidine compounds of formula (1)

(I)

in which

R independently of one another mean hydrogen, fluorine, chlorine, bromine, straight-chain or branched (C₁ - C₅) - alkyl, which in a given case is substituted with fluorine, chlorine,

or bromine, with a (C₁ - C₅) - alkyl-ether group and/or with phenyl; straight-chain or branched (C₂ - C₅) - alkenyl, which in a given case is substituted with fluorine, chlorine, or bromine, with a (C₁ - C₅) - alkyl ether group and/or phenyl; phenyl, which in a given case is substituted with fluorine, chlorine, bromine, (C₁ - C₅) - alkyl, -COOH, (C₁ - C₅) - alkyl ester, -NH₂, a mono- (C₁ - C₅) - alkyl substituted amine and/or a di-(C₁ - C₅) - alkyl substituted amine; a hetero-aromatic, which is bonded directly or via straight-chain or branched (C₁ - C₅) - alkylene to the pyridine and/or the phenyl ring, and contains a nitrogen atom and/or a sulfur atom and/or 1, 2, or 3 nitrogen atoms and contains a nitrogen atom and/or a sulfur atom and/or 1, 2, or 3 nitrogen atoms and a 5- or 6-member ring system which in a given case is substituted with fluorine, chlorine, bromine, (C₁ - C₅) - alkyl, -COOH, (C₁ - C₅) - alkyl ester, -NH₂, a mono- (C₁ - C₅) - alkyl substituted amine and/or a di-(C₁ - C₅) - alkyl substituted amine, or two R substituents bonded to the same ring form an aromatic or hetero-aromatic ring, which in a given case is substituted with fluorine, chlorine, bromine, (C₁ - C₅) - alkyl, -COOH, (C₁ - C₅) - alkyl ester, -NH₂, a mono- (C₁ - C₅) - alkyl substituted amine and/or a di-(C₁ - C₅) - alkyl substituted amine;

Y means -(CH₂)_n -, in which n = 0, 1, 2, or 3; oxygen, sulfur; vinyl; CH₂-O; -O-CH₂; -CH₂-, or -S-CH₂;

Z independently of one another mean hydrogen, -C(O)R¹; -C(O)OR¹; -O)S(O)R²; or one of the meanings of R¹;

R¹ independently of one another mean straight-chain or branched (C₁ - C₅) - alkyl, which in a given case is substituted with fluorine, chlorine, or bromine, with a (C₁ - C₅) - alkyl ether group, and/or with phenyl; straight-chain or branched (C₂ - C₅) - alkenyl, which in a given case is substituted with fluorine, chlorine, or bromine, with a (C₁ - C₅) - alkyl ether group, and/or phenyl; ; phenyl, which in a given case is substituted with fluorine, chlorine, bromine, (C₁ - C₅) - alkyl, -COOH, (C₁ - C₅) - alkyl ester, -NH₂, a mono- (C₁ - C₅) - alkyl substituted amine and/or a di-(C₁ - C₅) - alkyl substituted amine; a hetero-aromatic, which is bonded directly or via straight-chain or branched (C₁ - C₅) - alkylene to the pyridine and/or the phenyl ring, and contains a nitrogen atom and/or a sulfur atom and/or 1, 2, or 3 nitrogen atoms and contains a nitrogen atom and/or a sulfur atom and/or 1, 2, or 3 nitrogen atoms and a 5- or 6-member ring system which in a given case is substituted with fluorine, chlorine, bromine, (C₁ - C₅) - alkyl, -COOH, (C₁ - C₅) - alkyl ester, -NH₂, a mono- (C₁ - C₅) - alkyl substituted amine and/or a di-(C₁ - C₅) - alkyl substituted amine, or straight-chain or branched (C₁ - C₅) - alkyl, which is substituted by such a hetero-aromatic.

R² means one of the meanings of R¹, or a bridged saturated isocyclic system, which preferably is derived from camphor sulfonic acid;

which is characterized by the fact that a compound of formula (II)

(II)

in which the substituents R and Y have the meanings cited above, which a compound of formula (III)

(III)

in which Z has the meaning specified above, is brought to react in a single process step by means of reductive dimerization (i) in the presence of a finely dispersed metal compound of the IVth and/or Vth and/or VIth subgroup of the periodic table of elements or a low-valent oxidation stage of such a corresponding metal compound, (ii) the finely dispersed metal or the low-valent oxidation stage being produced *in situ* by means of a reducing agent and (iii) in the presence of an inert solvent, the reducing agent being chosen from the group of alkali metals, the metals of the IIInd main group or IIInd sub-group of the periodic table, alloys of these metals, alloys of these metals with zinc, zinc-copper alloys, inclusion compounds of such metals with carbon, preferably potassium-graphite inclusion compounds, metal hydrides, salts of naphthalidone ions or of higher polycyclic aromatics and the solvent being chosen from the group of inert ethers, preferably 1,4-dioxane, 1,2-dimethoxyethane, tetrahydrofurane, diethylene glycol dimethyl ether, tert.-butyl-methyl ether, or the group of nitrogen-containing unsaturate hetero-aromatics, preferably pyridine or tertiary amines, preferably triethyl amine.

The smooth conversion of amide, sulfonamide, and urethane substituted piperidine derivatives even in the case of long reaction times is surprising for the reaction in accordance with the invention, in particular since it is known that these functional groups are decomposed slowly under the chosen reaction conditions (cf. John E. McMurry, Carbonyl-Coupling, Reactions Using Low-Valent Titanium, Chem. rev. 89, p. 1513-1524 (1989), in particular pages 1515 ff). However, for the reactions described in this patent no decomposition can be observed even in the case of very long reaction times (>96 hours). In general, only a few successful coupling reactions of carbonyl compounds, which are substituted with the functional groups designated above, with low-valent titanium compounds, are known in the literature. Equally surprising are the high yields in the case of using titanium tetrachloride (TiCl₄). In the literature preference is given to the very unstable, oxidation-sensitive titanium trichloride (TiCl₃), which is little suited for industrial production. Yields which are comparably as good as those described in this patent are found in the literature in particular with the use of titanium trichloride.

Titanium, zirconium, vanadium, molybdenum, tungsten, and uranium are particularly well suited as metals, respectively metal compounds of the IVth, Vth, and VIth sub-groups of the periodic table, preferably halogen compounds thereof, preferably the chloride being used. The use of titanium tetrachloride is preferred, a low-valent stage of this compound, respectively of these named compounds, being created *in situ* by means of a reducing agent.

Preferably zinc or alkali metals, preferably zinc, lithium, sodium, or potassium; metals of main

group II or sub-group II of the periodic table, in particular magnesium or calcium; alloys containing zinc, lithium, sodium, potassium, magnesium, and/or calcium; zinc-copper alloys; inclusion compounds of zinc, lithium, sodium, potassium, magnesium, and/or calcium with carbon, in particular alkali metal hydrides or lithium aluminum hydride; salts of naphthalide anions, preferably lithium naphthalide or sodium naphthalide, are used as reducing agents.

Preferably inert ethers, preferably 1,4-dioxane, 1,2-dimethoxyethane, diethylene glycol dimethyl ether (diglyme), tert.-butyl methyl ether, as well as nitrogen-containing unsaturated hetero-aromatics, preferably pyridine or tertiary amides, preferably triethyl amine, are used as solvents.

The ratio of the compound of formula III) (in mol- equivalents) to the coupling metal compound (in equivalents, oxidation state +III or +IV) preferably amounts to 3 : 1 to 1 : 100, preferably 1 : 3, in performing the reaction.

The ratio of the reducing agent (in reduction equivalents) to the coupling metal compound (in equivalents, oxidation stage +III or +IV) preferably amounts to 1: 2 to 100 : 1, preferably 2 : 1, in performing the reaction.

The reaction temperature amounts to 0° C to 200°C, preferably 10°C to 100 °C, and in particular around 20°C to 70°C.

In the cited formulas of compounds (I) to (II), R means, preferably and independently of one another, hydrogen, fluorine, chlorine, bromine, methyl, or trifluoromethyl, particularly preferably R means, independently of one another, hydrogen, fluorine, or chlorine. The compound of formula (I) preferably has two substituents, which are different from hydrogen, one substituent R being on the pyridine ring and one substituent R being on the benzene ring, and the latter substituent preferably being fixed in 8-position. Preferably the compound of formula (I) has only one substituent R, which is found preferably in 8-position, and preferably means fluorine or chlorine.

The preferred meaning of Y is $-\text{CH}_2-\text{CH}_2-$;

Preferably R^1 means $(\text{C}_1 - \text{C}_5)$ - alkyl and, in particular, ethyl.

Preferably R^2 means $(\text{C}_1 - \text{C}_5)$ - alkyl, benzyl, vinyl, or dimethyl amino $(-\text{N}(\text{CH}_3)_2)$, in particular methyl.

Preferably Z means $-\text{C}(\text{O})\text{R}^1$; $-\text{C}(\text{O})\text{OR}^1$, preferably $-\text{C}(\text{O})\text{OR}^1$. For the most part preferably Z means a radical of the formula $-\text{C}(\text{O})-\text{C}_2\text{H}_5$.

$(\text{C}_1 - \text{C}_5)$ - alkyl means methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert.-butyl, n-pentyl, or branched pentyl, preferably methyl, ethyl, or propyl, preferably methyl or ethyl. $(\text{C}_2 - \text{C}_3)$ - alkenyl preferably means $(\text{C}_2 - \text{C}_3)$ - alkenyl and preferably (C_3) - alkenyl.

8-chlorine-substituted compounds and, in particular, the compound 4-(8-chloro-5,6-dihydro-

11*H*-benzo-[5,6]-cyclohepta-[1,2-*b*]pyridine-11-ylidene)-1-piperidine carboxylic acid ethyl ester, are preferred compounds of formula (1)..

The production of the compound can take place in four stages in formula (I), in which Y is -CH₂-CH₂. In a first stage a cyanide-substituted compound of formula (IV)

(IV)

in which the substituents R have the meaning specified above, is brought to react with a benzaldehyde compound of formula (V)

(V)

in which R has the meaning cited above, by means of a base-induced aldol condensation, preferably in the presence of potassium tert.-butylene, with simultaneous saponification of the nitrile group to the amide, to the compound of formula (VI):

(VI)

In the second stage the double bond of the compound of formula (VI) is hydrated on a palladium catalyst, without the other substituents, which are found on the benzoring, being hydrated or split off. In this way the amide of the compound of formula (VII) is obtained:

(VII)

In the third stage the amide of formula (VII) is hydrolyzed in a basic medium, the carboxylic acid of the compound of formula (VIII) being obtained.

(VIII)

In the fourth stage the compound of formula (VIII) is converted into the corresponding acid chloride by means of thionyl chloride (SOCl_2), and cyclized to the tricycle of formula (IX) by means of a Friedel-Crafts reaction in the presence of aluminum chloride.

(IX)

In the compound of formula (IV) R = hydrogen and 3-chloro-benzaldehyde is used as a compound of formula (V), thus 8-chloro-5,6-dihydro-11*H*-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-one is obtained. If this compound is made to react with 1-(ethoxycarbonyl)-4-piperidone, that is a compound of formula (III), in which Z means ethoxycarbonyl, 4-(8-chloro-5,6-dihydro-11*H*-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-ylidene)-1-piperidine carboxylic acid ethyl ester (loratadine) is obtained. The production of this compound is a preferred embodiment of the present invention.

Compounds of formula (II), in which Y is oxygen, sulfur, vinyl, $\text{CH}_2\text{-O}$; -O-CH_2 ; $\text{-CH}_2\text{-}$, or -S-CH_2 , can be produced in a way known per se. The following examples explain the invention.

Example I:

4-(5,6-dihydro-11*H*-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-ylidene)-1-piperidine carboxylic acid ethyl ester

10.11 g (155 mmol) of powdered zinc and 13.04 g (69 mmol) of titanium tetrachloride are heated to boiling in 65 g of absolute tetrahydrofuran (THF) under a protective gas atmosphere. As soon as the solution is colored black, it is cooled to room temperature. 5.25 g (25 mmol) of 5,6-dihydro-11*H*-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-one and 4.25 g (25 mmol) of 1-(ethoxycarbonyl)-4-piperidone are to be added. The preparation is stirred over night at room

temperature and then 5 hours at 40°C. The preparation is concentrated in 60 g of ethyl acetate, dissolved in 60 g of ethyl acetate, and diluted with 100 g of a saturated aqueous solution of ethylene diamino-tetra acetic acid-tetra sodium salt-dihydrate. After the heat development dies down, the organic phase is separated, and the aqueous phase is rewashed two times with 20 g of ethyl acetate. The aqueous phase then is treated with 30% hydrogen peroxide solution, until the gray-colored low-valent titanium compounds have reacted completely to the white titanium (IV) dioxide, and discarded. The combined organic phases are dried over sodium sulfate, filtered, and concentrated to dry. In this case the product is separated as a semicrystalline syrup. The latter is dissolved in 40g of ethyl acetate / diisopropyl ether and heated to the reflux. After the addition of activated charcoal and hot filtration, the product precipitates out in the form of colorless crystals (in a given case after seeding). Yield: 5,9% (68%); HPLC-purity 94%, melting point 108°C-109°C.

Example 2

4-(8-chloro-5,6-dihydro-11H-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-ylidene)-1-piperidine carboxylic acid ethyl ester

In accordance with Example 1, 40.0 g (160 mmol) of 8-chloro-5,6-dihydro-11H-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-one and 27.4 g (160 mmol) 1-(ethoxy)-4-piperidone are brought to react with a coupling reagent consisting of 53.6 g (820 mmol) zinc and 75.9g (400 mmol) of titanium tetrachloride. After cooling and crystallization out of ethyl acetate / diisopropyl ether (in a given case after seeding), 4-(8-chloro-5,6-dihydro-11H-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-ylidene)-1-piperidine carboxylic acid ethyl ester is obtained in a yield of 47.2 g (75%); HPLC purity 97%; as colorless crystals, melting point 136°C - 138°C.

Example 3

4-(8-fluoro-5,6-dihydro-11H-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-ylidene)-1-piperidine carboxylic acid ethyl ester

In accordance with Example 1, 27.35 g (119 mmol) of 8-fluoro-5,6-dihydro-11H-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-one and 20.0 g (117 mmol) 1-(ethoxy)-4-piperidone are brought to react with a coupling reagent consisting of 37.0 g (566 mmol) zinc and 50.9g (268 mmol) of titanium tetrachloride. After cooling and crystallization out of ethyl acetate / diisopropyl ether (in a given case after seeding), 4-(8-fluoro-5,6-dihydro-11H-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-ylidene)-1-piperidine carboxylic acid ethyl ester is obtained in a yield of 38.0 g (67%); HPLC purity 96%; as colorless crystals, melting point 119°C - 121°C.

Example 4

4-(8-chloro-5,6-dihydro-11H-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-ylidene)-1-acetyl piperidine

31.7g of zinc-copper alloy and 24.1g (156 mmol) of titanium chloride are heated to boiling in 175 g of absolute tetrahydrofuran (THF) under protective gas atmosphere. As soon as the solution is colored black, it is cooled to room temperature. 15.31g (63 mmol) 8-chloro-5,6-dihydro-11H-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-one and 8.90 g (63 mmol) of 1-acetyl-1-piperidone are to be added. It is stirred for 3 hours at room temperature and then for 6 hours at 50°C. The preparation is concentrated, dissolved in 120 g of ethyl acetate, and diluted with 250

g of a saturated aqueous solution of ethylene diamino-tetra acetic acid-tetra sodium salt-dihydrate. After the heat development dies down, the organic phase is separated and the aqueous phase is rewashed two times with 30 g of ethyl acetate. The aqueous phase then is treated with 30% hydrogen peroxide solution, until the gray-colored low-valent titanium compounds have reacted completely to the white titanium (IV) dioxide, and discarded. The combined organic phases are dried over sodium sulfate, filtered, and concentrated to dry. After cooling and crystallization out of ethyl acetate / diisopropyl ether (in a given case after seeding), 4-(8-chloro-5,6-dihydro-1*H*-benzo-[5,6]-cyclohepta-[1,2-*b*]pyridine-11-ylidene-1)-1-acetyl-piperidine is obtained in a yield of 16.00 g (72%); HPLC purity 96%; as colorless crystals, melting point 161°C - 162°C. Remark : all melting points in examples 1 to 4 are uncorrected.

Patent Claims

1. A process for creating 1,4-disubstituted piperidine compounds of formula (1)

(I)

in which

- R independently of one another mean hydrogen, fluorine, chlorine, bromine, straight-chain or branched (C₁ - C₅) - alkyl, which in a given case is substituted with fluorine, chlorine, or bromine, with a (C₁ - C₅) - alkyl-ether group and/or with phenyl; straight-chain or branched (C₂ - C₅) - alkenyl, which in a given case is substituted with fluorine, chlorine, or bromine, with a (C₁ - C₅) - alkyl ether group and/or phenyl; phenyl, which in a given case is substituted with fluorine, chlorine, bromine, (C₁ - C₅) - alkyl, -COOH, (C₁ - C₅) - alkyl ester, -NH₂, a mono- (C₁ - C₅) - alkyl substituted amine and/or a di-(C₁ - C₅) - alkyl substituted amine; a hetero-aromatic, which is bonded directly or via straight-chain or branched (C₁ - C₅) - alkylene to the pyridine and/or the phenyl ring, and contains a nitrogen atom and/or a sulfur atom and/or 1, 2, or 3 nitrogen atoms and contains a nitrogen atom and/or a sulfur atom and/or 1, 2, or 3 nitrogen atoms and a 5- or 6-member ring system which in a given case is substituted with fluorine, chlorine, bromine, (C₁ - C₅) - alkyl, -COOH, (C₁ - C₅) - alkyl ester, -NH₂, a mono- (C₁ - C₅) - alkyl substituted amine and/or a di-(C₁ - C₅) - alkyl substituted amine, or two R substituents bonded to the same ring form an aromatic or hetero-aromatic ring, which in a given case is substituted with fluorine, chlorine, bromine, (C₁ - C₅) - alkyl, -COOH, (C₁ - C₅) - alkyl ester, -NH₂, a mono- (C₁ - C₅) - alkyl substituted amine and/or a di-(C₁ - C₅) - alkyl substituted amine;
- Y means -(CH₂)_n -, in which n = 0, 1, 2, or 3; oxygen, sulfur; vinyl; CH₂-O; -O-CH₂; -CH₂-, or -S-CH₂;
- Z independently of one another mean hydrogen, -C(O)R¹; -C(O)OR¹; -O)S(O)R²; or one of the meanings of R¹;
- R¹ independently of one another mean straight-chain or branched (C₁ - C₅) - alkyl, which in a given case is substituted with fluorine, chlorine, or bromine, with a (C₁ - C₅) - alkyl ether group, and/or with phenyl; straight-chain or branched (C₂ - C₅) - alkenyl, which in a given case is substituted with fluorine, chlorine, or bromine, with a (C₁ - C₅) - alkyl ether group, and/or phenyl; phenyl, which in a given case is substituted with fluorine, chlorine, bromine, (C₁ - C₅) - alkyl, -COOH, (C₁ - C₅) - alkyl ester, -NH₂, a mono- (C₁ - C₅) - alkyl substituted amine and/or a di-(C₁ - C₅) - alkyl substituted amine; a hetero-aromatic, which is bonded directly or via straight-chain or branched (C₁ - C₅) - alkylene to the pyridine and/or the phenyl ring, and contains a nitrogen atom and/or a sulfur atom and/or 1, 2, or 3 nitrogen atoms and contains a nitrogen atom and/or a sulfur atom and/or

1, 2, or 3 nitrogen atoms and a 5- or 6-member ring system which in a given case is substituted with fluorine, chlorine, bromine, (C₁ - C₅) - alkyl, -COOH, (C₁ - C₅) - alkyl ester, -NH₂, a mono- (C₁ - C₅) - alkyl substituted amine and/or a di-(C₁ - C₅) - alkyl substituted amine, or straight-chain or branched (C₁ - C₅) - alkyl, which is substituted by such a hetero-aromatic.

R² means one of meanings of R¹, or a bridged saturated isocyclic system, which preferably is derived from camphor sulfonic acid;

wherein a compound of formula (II)

(II)

in which the substituents R and Y have the meanings cited above, with a compound of formula (III)

(III)

in which Z has the meaning specified above, is brought to react in a single process step by means of reductive dimerization (i) in the presence of a finely dispersed metal compound of the IVth and/or Vth and/or VIth subgroup of the periodic table of elements or a low-valent oxidation stage of such a corresponding metal compound, (ii) the finely dispersed metal or the low-valent oxidation stage being produced *in situ* by means of a reducing agent, and (iii) in the presence of an inert solvent, the reducing agent being chosen from the group of alkali metals, metals of the IInd main group or IInd subgroup of the periodic table, alloys of these metals, inclusion compounds of such metals, or of higher polycyclic aromatics, and the solvent is chosen for the group of the inert ethers or the group of nitrogen-containing unsaturated hetero-aromatics or the tertiary amines.

2. The process in accordance with Patent Claim 1, wherein R independently of one another means hydrogen, fluorine, chlorine, bromine, methyl, or trifluoromethyl.

3. The process in accordance with Patent Claim 1, wherein R independently of one another means hydrogen, fluorine, or chlorine.

4. The process in accordance with one of the Patent Claims 1 or 2, wherein the compound of

formula (1) has two substituents R, which are different from hydrogen, one substituent R being on the pyridine ring and one substituent R on the benzoring.

5. The process in accordance with Patent Claim 4, wherein the substituent R is fixed on the benzoring in 8-position.
6. The process in accordance with one of the Patent Claims 1 to 3, wherein the compound of formula (1) only has a single substituent R, which is different from hydrogen, this substituent R being fixed in R-position.
7. The process in accordance with one of the Patent Claims 1 to 6, wherein

Y means $-\text{CH}_2-\text{CH}_2-$;

R^1 means $(\text{C}_1 - \text{C}_5)$ -alkyl, preferably ethyl;

R^2 means $(\text{C}_1 - \text{C}_5)$ -alkyl, benzyl, vinyl, or dimethyl amino, preferably methyl;

Z means $-\text{C}(\text{O})\text{R}^1$; $-\text{C}(\text{O})\text{OR}^1$, preferably $-\text{C}(\text{O})\text{OR}^1$, and preferably $-\text{C}(\text{O})-\text{C}_2\text{H}_5$.

8. The process in accordance with one of the Patent Claims 1 to 7, wherein a halogen compound is used as the metal compound.
9. The process in accordance with Patent Claim 8, wherein a chloride of titanium, zirconium, vanadium, molybdenum, tungsten, and/or uranium is used as metal compound.
10. The process in accordance with Patent Claim 8, wherein titanium chloride is used as a metal compound and a low-valent stage of this compound is created *in situ* by means of a reducing agent.
11. The process in accordance with one of the Patent Claims 1 to 9, wherein zinc, lithium, sodium, potassium, magnesium, or calcium or alloys containing zinc, lithium, sodium, potassium, magnesium, and/or calcium, calcium hydride, sodium borohydride, or lithium aluminum hydride is used as reducing agent.
12. The process in accordance with one of the patent Claims 1 to 9, wherein an alloy of an alkali metal, a metal of the IIInd main group, or the IIInd subgroup of the periodic table with zinc, a zinc-copper alloy, or a potassium-graphite inclusion compound is the reducing agent.
13. The process in accordance with one of the patent Claims 1 to 12, wherein 1,4-dioxane, 1,2-dimethoxyethane, tetrahydrofurane, diethylene glycol dimethyl ether, tert.-butyl-methyl ether, pyridine, or triethyl amine is used as solvent.
14. The process in accordance with one of the Patent Claims 1 to 13, wherein the compound 4-(8-fluoro-5,6-dihydro-11H-benzo-[5,6]-cyclohepta-[1,2-b]pyridine-11-ylidene)-1-piperidine carboxylic acid ethyl ester is produced.
15. The compounds produced in accordance with one of the Patent Claims 1 to 14

Docket No.
ABJ-136

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PROCESS FOR PREPARING 1,4- DISUBSTITUTED PIPERIDINE COMPOUNDS

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on September 9, 1999 as United States Application No. or PCT International
Application Number 09/380,835
and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

571/97
(Number)

Switzerland
(Country)

11/03/97
(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

_____ (Application Serial No.)	_____ (Filing Date)
_____ (Application Serial No.)	_____ (Filing Date)
_____ (Application Serial No.)	_____ (Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Anthony M. Lorusso Reg. No. 25,059

George A. Loud Reg. No. 25,814

Thomas A. Saunders Reg. No. 29,585

Donald J. Perreault Reg. No. 40,126

Mark D. Lorusso Reg. No. 41,955

Send Correspondence to:

LORUSSO & LOUD

440 commercial St.

Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

Anthony M. Lorusso (617) 227-0700

Full name of sole or first inventor

Max REY

Sole or first inventor's signature

Residence

Manessestrasse 4, CH-8003 Zurich, SWITZERLAND

Citizenship

Swiss

Post Office Address

same as above

Date

01/19/00

Full name of second inventor, if any

Stefan GLADOW

Second inventor's signature

Residence

Kornstrasse 1, CH-9470 Buchs, SWITZERLAND

Citizenship

German

Post Office Address

same as above

Date

01/20/2000